Grants and Contributions:
Title:
Monoclonal antibody to reverse tumor immunosuppression in cancer
Agreement Number:
892718
Agreement Value:
$203,000.00
Agreement Date:
Sep 1, 2017 - Mar 31, 2019
Description:
A monoclonal antibody to block tumor-associated immunosuppression by altering immune cell development will be developed in preparation for preclinical development and clinical trials.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
North Vancouver, British Columbia, CA V7L 4B4
Reference Number:
172-2018-2019-Q2-892718
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
837332592
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 16 days. The total amended value is 9,000 dollars.
Amendment Date
Mar 11, 2019
Recipient's Legal Name:
ME Therapeutics Inc.
Federal Riding Name:
North Vancouver
Federal Riding Number:
59021
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: